MedinCell at the 2023 Jefferies Global Healthcare Conference - London, 14-16 November
06 November 2023 - 6:27PM
Business Wire
- Christophe Douat, CEO, and Richard Malamut, CMO, will
present MedinCell's commercial and advanced-development stage
portfolio at the Jefferies London Healthcare Conference on
November 16 at 1:30pm GMT
- Investors can access the presentation remotely, either live
or on replay, via the following link:
https://wsw.com/webcast/jeff287/medcl/1983116
- MedinCell management team will be available for individual
interviews with investors throughout the conference
Regulatory News:
MedinCell (Paris:MEDCL) has recently reached the commercial
stage with the market launch by Teva of UZEDY™ for the treatment of
schizophrenia. UZEDY is the first innovative product based on
MedinCell’s long-acting injectable (LAI) BEPO® technology approved
by US FDA.
In parallel, MedinCell is developing a portfolio of innovative
treatments also using the BEPO technology. This notably includes
the following candidate treatments:
2 candidates in clinical Phase 3:
- mdc-TJK: Potentially, the first long-acting injectable
olanzapine with a favorable safety profile that could enable a
large adoption for treatment of patients with more severe forms of
schizophrenia
- mdc-CWM: An innovative sustained-release formulation of a
non-steroidal anti-inflammatory drug celecoxib aiming at
facilitating patient recovery after total knee replacement and
decreasing the need for potentially addictive opioids
3 candidates ready for Phase 1 studies in 2024:
- mdc-WWM: 6-month active subcutaneous contraceptive
- mdc-GRT: Monthly subcutaneous tacrolimus LAI to prevent solid
organ graft rejection
- mdc-STM: Global Health program to fight malaria
Other programs are currently in the evaluation and formulation
stage, some as part of the internal program development strategy,
others within the framework of partnerships.
About MedinCell
MedinCell is a clinical- and commercial-stage biopharmaceutical
company developing long-acting injectable drugs in many therapeutic
areas. Our innovative treatments aim to guarantee compliance with
medical prescriptions, to improve the effectiveness and
accessibility of medicines, and to reduce their environmental
footprint. They combine already known and used active ingredients
with our proprietary BEPO® technology which controls the delivery
of a drug at a therapeutic level for several days, weeks or months
from the subcutaneous or local injection of a simple deposit of a
few millimeters, entirely bioresorbable. The first treatment based
on BEPO technology, intended for the treatment of schizophrenia,
was approved by the FDA in April 2023, and is now distributed in
the United States by Teva under the name UZEDY™ (BEPO technology is
licensed to Teva under the name SteadyTeq™).
We collaborate with leading pharmaceutical companies and
foundations to improve global health through new treatment options.
Based in Montpellier, MedinCell currently employs more than 140
people representing more than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
www.medincell.com
This press release contains forward-looking statements,
including statements regarding Company’s expectations for (i) the
timing, progress and outcome of its clinical trials; (ii) the
clinical benefits and competitive positioning of its product
candidates; (iii) its ability to obtain regulatory approvals,
commence commercial production and achieve market penetration and
sales; (iv) its future product portfolio; (v) its future partnering
arrangements; (vi) its future capital needs, capital expenditure
plans and ability to obtain funding; and (vii) prospective
financial matters regarding our business. Although the Company
believes that its expectations are based on reasonable assumptions,
any statements other than statements of historical facts that may
be contained in this press release relating to future events are
forward-looking statements and subject to change without notice,
factors beyond the Company's control and the Company's financial
capabilities. These statements may include, but are not limited to,
any statement beginning with, followed by or including words or
phrases such as "objective", "believe", "anticipate", “expect”,
"foresee", "aim", "intend", "may", "anticipate", "estimate",
"plan", "project", "will", "may", "probably", “potential”,
"should", "could" and other words and phrases of the same meaning
or used in negative form. Forward-looking statements are subject to
inherent risks and uncertainties beyond the Company's control that
may, if any, cause actual results, performance, or achievements to
differ materially from those anticipated or expressed explicitly or
implicitly by such forward-looking statements. A list and
description of these risks, contingencies and uncertainties can be
found in the documents filed by the Company with the Autorité des
Marchés Financiers (the "AMF") pursuant to its regulatory
obligations, including the Company's registration document,
registered with the AMF on September 4, 2018, under number I.
18-062 (the "Registration Document"), as well as in the documents
and reports to be published subsequently by the Company. In
particular, readers' attention is drawn to the section entitled
"Facteurs de Risques" on page 26 of the Registration Document. Any
forward-looking statements made by or on behalf of the Company
speak only as of the date they are made. Except as required by law,
the Company does not undertake any obligation to publicly update
these forward-looking statements or to update the reasons why
actual results could differ materially from those anticipated by
the forward-looking statements, including in the event that new
information becomes available. The Company's update of one or more
forward-looking statements does not imply that the Company will
make any further updates to such forward-looking statements or
other forward-looking statements. Readers are cautioned not to
place undue reliance on these forward-looking statements. This
press release is for information purposes only. The information
contained herein does not constitute an offer to sell or a
solicitation of an offer to buy or subscribe for the Company's
shares in any jurisdiction, in particular in France. Similarly,
this press release does not constitute investment advice and should
not be treated as such. It is not related to the investment
objectives, financial situation, or specific needs of any
recipient. It should not deprive the recipients of the opportunity
to exercise their own judgment. All opinions expressed in this
document are subject to change without notice. The distribution of
this press release may be subject
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106685240/en/
David Heuzé - Head of Communications
david.heuze@medincell.com / +33 (0)6 83 25 21 86
Media Relations Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Investor Relations France Louis-Victor
Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71
94 94
Head of US Financial Strategy & IR Grace Kim
grace.kim@medincell.com / +1 (646) 991-4023
Medincell (EU:MEDCL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Medincell (EU:MEDCL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024